You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 28, 2025

Claims for Patent: 8,708,968

✉ Email this page to a colleague

Summary for Patent: 8,708,968

Title:	Removal of needle shields from syringes and automatic injection devices
Abstract:	Exemplary embodiments provide a needle shield remover that reliably engages with a distal cap of an automatic injection device and with one or more needle shields coupled to a syringe of the device. When a user removes the distal cap, the needle shield remover reliably removes the needle shields (e.g., a soft needle shield and a rigid needle shield) from the syringe, thereby exposing the injection needle for performing an injection. In an exemplary assembly method, a needle shield remover is engaged to a needle shield coupled to a syringe, prior to insertion of the syringe and needle shield remover assembly into a housing of the device. This exemplary assembly method allows visual inspection, outside the housing of the device, to ensure that the needle shield remover is correctly and reliably engaged to the needle shield before the syringe and needle shield remover assembly is inserted into the housing.
Inventor(s):	Julian Joseph F., Li Chuan, Anderson Philip D., Laurusonis Linas P., Raday Lior, Carmel Ehud, Marli Lior, Daily David, Keenan Guy
Assignee:	Abbvie Biotechnology Ltd.
Application Number:	US13357508
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,708,968

Details for Patent 8,708,968

Glossary

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	December 31, 2002	8,708,968	2032-01-24
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	February 21, 2008	8,708,968	2032-01-24
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	April 24, 2013	8,708,968	2032-01-24
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	September 23, 2014	8,708,968	2032-01-24
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	November 23, 2015	8,708,968	2032-01-24
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	March 09, 2016	8,708,968	2032-01-24
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 8,708,968

Subscribe to access the full database, or Get Started Free
Country	Patent Number	Estimated Expiration
South Africa	201607089	⤷ Get Started Free
South Africa	201607088	⤷ Get Started Free
South Africa	201305030	⤷ Get Started Free
World Intellectual Property Organization (WIPO)	2012103140	⤷ Get Started Free
World Intellectual Property Organization (WIPO)	2012101629	⤷ Get Started Free
United States of America	9339610	⤷ Get Started Free
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.